GlassScriptPhysician profile
John H Ashley
NPI 1861569956
$2,456.10
in general payments reported to CMS, 2019-2025
19 companies · $591 in 2025
The $591 reported for 2025 was more than what a typical Medical provider received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $223 · 2022: $550 · 2023: $368 · 2024: $725 · 2025: $591.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,684.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,683.64 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $637.12 | 2021-2025 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $618.42 | 2021-2025 | Lifevest |
| Boston Scientific Corporation | $147.23 | 2021-2025 | Watchman Flx |
| Abbott Laboratories | $142.11 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $125.62 | 2022-2025 | Eliquis, Camzyos |
| Cvrx, INC. | $115.99 | 2023-2025 | Barostim Neo System |
| Pfizer INC. | $92.16 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $91.71 | 2025 | |
| Abiomed | $86.22 | 2024 | Impella |
| Janssen Pharmaceuticals, INC | $68.06 | 2021-2022 | |
| Cardiva Medical, INC. | $67.48 | 2024 | Optowire, Savvywire |
| Medtronic, INC. | $67.17 | 2025 | Ffrangio |
| Shockwave Medical, INC | $57.75 | 2024 | Shockwave Ivl System With The Shockwave C2 Coronary Ivl Catheter |
| Astrazeneca Pharmaceuticals LP | $33.21 | 2022-2024 | Farxiga |
| Atricure, INC. | $32.09 | 2023 |
Show all 19 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Inspire Medical Systems, INC. | $21.33 | 2025 | Inspire |
| Gilead Sciences, INC. | $20.54 | 2021 | |
| Merck Sharp & Dohme LLC | $16.42 | 2025 | Verquvo |
| Kiniksa Pharmaceuticals, LTD. | $15.47 | 2023 | Arcalyst |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Ashley listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.